This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran A, et al. Levothyrox® new and old formulations: are they switchable for millions of patients? Clin Pharmacokinet. 2019. https://doi.org/10.1007/s40262-019-007747-3.
Lindenblatt, et al. Solid pharmaceutical preparation containing levothyroxine. United States Patent Application Publication. Merck patent GMBH. US 2015/0231101 A1. 2015.
ANSM. Direction des contrôles. 12/09/2017. Note de synthèse 17-A-033.
Zamfirescu I, Carlson HE. Absorption of levothyroxine when coadministrated with various calcium formulations. Thyroid. 2011;21:483–6.
Poole RA, Kasper PT, Jiskoot W. Formation of amide- and imide-linked degradation products between the peptide drug oxytocin and citrate in citrate-buffered formulations. J Pharm Sci. 2011;100:3018–22.
Chumsae C, Zhou LL, Shen Y, Wohlgemuth J, Fung E, Burton R, et al. Discovery of a chemical modification by citric acid in a recombinant monoclonal antibody. Anal Chem. 2014;86:8932–6.
No external funds were used in the preparation of this letter.
Conflict of interest
Philippe Tréchot declares no potential conflicts of interest that might be relevant to the contents of this letter.
Rights and permissions
About this article
Cite this article
Tréchot, P. Comment on: Levothyrox® New and Old Formulations: Are They Switchable for Millions of Patients?. Clin Pharmacokinet 58, 977–978 (2019). https://doi.org/10.1007/s40262-019-00784-y